Clinical Trial Update: Ketamine Challenge Study With JNJ-40411813 [Phase 1]

View source ↗

Summary

Phase 1 ketamine challenge study of JNJ-40411813 by Johnson & Johnson Pharmaceutical Research & Development has completed. The trial explored effects related to…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• JNJ-40411813

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Perceptual Disorders, Confusion | Phase 1 | Status: COMPLETED